Decision

UK REACH authorisation for Ortho-Clinical Diagnostics, 26 July 2021

Decision on application for authorisation under UK REACH.

Applies to England, Scotland and Wales

Documents

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Decision on a transitional application for authorisation under UK REACH.

Substance name

4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated.

Authorised use

Formulation of 4-(1,1,3,3-Tetramethylbutyl) phenol, ethoxylated (as Triton X-100) for use in the manufacture of in vitro diagnostic VITROS庐 products used for infectious disease screening, endocrinology, and oncology testing.

Holder of the authorisation and authorisation number

Ortho-Clinical Diagnostics (UKREACH/21/01/0) .

Date of decision

26 July 2021

Updates to this page

Published 3 August 2021

Sign up for emails or print this page